Related Experiment Videos

Tocolytic agents and the failure to improve neonatal outcomes

Jack FitzSimmons1, Emily Oliver2

  • 1Department of Obstetrics and Gynecology, Jefferson Abington Abington Pennsylvania USA.

Pregnancy (Hoboken, N.J.)
|August 14, 2026
PubMed

Insights

Despite decades of research and numerous studies, no tocolytic agent has proven effective in improving neonatal outcomes for premature delivery. Current practices lack evidence, increasing costs and hindering research.

Area of Science:

  • Obstetrics
  • Perinatal Medicine
  • Clinical Pharmacology

Background:

  • Premature delivery is a significant obstetric challenge, leading to increased perinatal morbidity, mortality, and healthcare costs.
  • Despite extensive research over 70 years, no tocolytic agent has demonstrated clear benefits for neonates.
  • The widespread clinical use of unproven tocolytic agents constitutes the standard of care, despite a lack of efficacy.

Purpose of the Study:

  • To review the history of research into tocolytic agents for premature delivery.
  • To highlight the deficiencies in the current methodologies for studying tocolytic agents.
  • To propose a more rational approach to the development of drugs for preventing premature birth.

Main Methods:

  • Review of historical clinical trials and publications on tocolytic agents.
  • Analysis of the impact of unproven treatments on healthcare costs and patient harm.
  • Discussion of challenges in conducting placebo-controlled trials for tocolytic agents.

Main Results:

  • No tocolytic medication has shown a demonstrable benefit to neonates in clinical studies.
  • The established use of ineffective tocolytic agents has increased healthcare expenditures.
  • Lack of proven efficacy has complicated the design and execution of rigorous clinical trials.

Conclusions:

  • The current approach to developing tocolytic agents is flawed, characterized by a lack of evidence-based efficacy.
  • Continued use of medications without proven benefits contributes to unnecessary costs and potential harm.
  • A paradigm shift towards more rational drug development strategies is essential for advancing the treatment of premature delivery.

Keywords:
premature laborprematuritypreterm deliverytocolysis

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...